Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;2(2):157-61.
doi: 10.1007/s13167-011-0084-z. Epub 2011 May 18.

Biomarker development for non-invasive prenatal diagnosis of fetal aneuploidies: predictive reliability and potential clinical application

Aggeliki Kolialexi  1 , Athanasios K Anagnostopoulos, Georgia Tounta, Aris Antsaklis, Ariadni Mavrou, George Th Tsangaris
Affiliations

Biomarker development for non-invasive prenatal diagnosis of fetal aneuploidies: predictive reliability and potential clinical application

Aggeliki Kolialexi et al. EPMA J. 2011 Jun.

Abstract

Current non-invasive prenatal diagnosis for fetal aneuploidies is based on biochemical and ultrasound markers and needs to be improved in order to reduce the number of pregnant women subjected to invasive diagnostic procedures. Proteomic technologies allow for new strategies for discovering biomarkers in complex biological fluids in a high-throughput and sensitive manner. Application of advance proteomic tools to profile pathology-specific proteins in maternal plasma obtained from pregnancies with aneuploid fetuses revealed biomarker-candidates that can potentially revolutionize the diagnostic and treatment procedure in favor of better prediction and improved individual outcomes. The current review focuses on studies of maternal peripheral blood using proteomic technologies, describes alterations noted in the presence of fetal aneuploidies and discuss their potential use as biomarkers for non-invasive prenatal diagnosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
2D-E regions including spots with different intensity in maternal plasma samples from women known to carry normal and DS fetuses. Differentially expressed spots correspond to Apo E and SAMP (From [17] copyright Willey. reproduced with permission)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Faas BH, Cirigliano V, Bui TH. Rapid methods for targeted prenatal diagnosis of common chromosome aneuploidies. Semin Fetal Neonatal Med. 2011;16:81–87. doi: 10.1016/j.siny.2011.01.003. - DOI - PubMed
    1. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down’s syndrome with use of maternal serum markers. N Engl J Med. 1992;327:588–593. doi: 10.1056/NEJM199208273270902. - DOI - PubMed
    1. Verp MS, Bombard AT, Simpson JL, Elias S. Parental decision following prenatal diagnosis of fetal chromosome abnormality. Am J Med Genet. 1988;29:613–622. doi: 10.1002/ajmg.1320290320. - DOI - PubMed
    1. D’Alton M, Cleary-Goldman J. First and second trimester evaluation of risk for fetal aneuploidy: the secondary outcomes of the FASTER Trial. Semin Perinatol. 2005;29:240–246. doi: 10.1053/j.semperi.2005.06.006. - DOI - PubMed
    1. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005;353:2001–2011. doi: 10.1056/NEJMoa043693. - DOI - PubMed

LinkOut - more resources